Trend of Burkholderia cepacia complex bacteremia between 2008-2021: Insights from a Major Pakistani Laboratory Network
DOI:
https://doi.org/10.61529/idjp.v34i3.388Abstract
Background: Burkholderia cepacia complex (BCC) is an opportunistic pathogen, primarily affecting neonates and immunocompromised patients. Limited data exist in Pakistan on its prevalence and resistance patterns. This retrospective study aimed to assess trends of BCC infection and antimicrobial resistance from 2008 to 2021.
Material and Methods: This retrospective study analyzed trends of Burkholderia cepacia complex (BCC) infections and their antimicrobial resistance at Aga Khan University Hospital, Pakistan, from 2008 to 2021. Antimicrobial susceptibility was tested using the Kirby–Bauer disc diffusion method against chloramphenicol, ceftazidime, ciprofloxacin, minocycline, meropenem, trimethoprim-sulfamethoxazole, and tetracycline, and interpreted per CLSI guidelines. Data were processed in SPSS version 19.0, with frequencies and percentages calculated to assess laboratory-confirmed BCC cases.
Results: A total of 5411 BCC strains were isolated from blood cultures during a period of 2008–2021. We observed that neonates were the predominant age group (47-76%) almost each year for BCC bacteremia. This study observed highest resistance (up to 37%) in BCC strains against levofloxacin, isolated from both in-patients and out-patients. Higher meropenem resistance (37%) was found in in-patients isolates while 25% in out-patient isolates while ciprofloxacin resistance was higher (29% vs 20%) in outside referral blood cultures.
Conclusions: Continuous surveillance of Burkholderia cepacia complex (BCC) antibacterial resistance is essential to monitor the spread of resistance, as antimicrobial resistance imparts a very crucial role in the spread of infection to susceptible group.
Keywords: B. cepacia complex (BCC), Antimicrobial resistance, Neonates, Sepsis.
References
Lauman P, Dennis JJ. Advances in phage therapy: targeting the Burkholderia cepacia complex. Viruses. 2021; 13(7): 1331. DOI: https://doi.org/10.3390/v13071331
Gupta N, Yadav B, Sasidharan R, Tak V, Sharma A, Singh A, et al. P0655/#2074: emergence of Burkholderia cepacia complex sepsis among neonates: a retrospective cohort study. Pediatr Crit Care Med. 2021; 22 (Suppl 1 3S): 316–7. DOI: http://dx.doi.org/10.1097/01.pcc.0000740956.00861.54
Saran A, Agarwal A, Mali SA, Singhal L, Patil PB, Gautam V. Burkholderia cepacia complex nosocomial outbreaks in India: a scoping review. Indian J Med Res. 2025; 160(6): 593-605. DOI: https://doi.org/10.25259/ijmr_94_2024
Kwayess R, Al Hariri HE, Hindy JR, Youssef N, Haddad SF, Kanj SS, et al. Burkholderia cepacia infections at sites other than the respiratory tract: A large case series from a tertiary referral hospital in Lebanon. J Epidemiol Glob Health. 2022; 12(3): 274–80. DOI: https://doi.org/10.1007/s44197-022-00048-2
Ibrahim T, Abdallah TA, Abdallah A, Qazi R, Alimam A, Mohammad H, et al. Epidemiology, microbiological, clinical characteristics, and outcome of Burkholderia cepacia complex infections in non-cystic fibrosis adult patients from Qatar. IJID Reg. 2024; 11: 100355. DOI: https://doi.org/10.1016/j.ijregi.2024.03.010
Seelman SL, Bazaco MC, Wellman A, Hardy C, Fatica MK, Huang MC, et al. Burkholderia cepacia complex outbreak linked to a no-rinse cleansing foam product, United States–2017–2018. Epidemiol Infect. 2022; 150: e154. DOI: https://doi.org/10.1017/s0950268822000668
Centers for Disease Control and Prevention. Nosocomial Burkholderia cepacia infection and colonization associated with intrinsically contaminated mouthwash—Arizona, 1998. MMWR Morb Mortal Wkly Rep. 1998; 47: 926–8. Available from: https://www.cdc.gov/mmwr/ preview/mmwrhtml/00055575.htm
Kömeç S, Ceylan AN, Özalp O, Durmuş MA, Gunduz A, Yavaş C, et al. Burkholderia cepacia outbreak in intensive care units, Türkiye. Available from: https://dx.doi.org/10.2139/ssrn.5033636
Aytaç Ö, Tanrıverdi ES, Gündağ Ö, Şenol FF, Karlıdağ GE, Otlu B. An intensive care outbreak caused by Burkholderia cepacia from bacterial filters. Pathogens. 2025; 14(3): 266. DOI: https://doi.org/10.3390/pathogens14030266
Helmy NA, Basyony AF, Tohamy ST, Zaki SA. In-vivo and in-vitro therapeutic perspectives in the treatment of Burkholderia cepacia complex infections: A review. Azhar Int J Pharm Med Sci. 2025; 5(1): 38–61. DOI: https://doi.org/10.21608/aijpms.2024.293015.1269
Santana JCG, Jiménez VRC. Burkholderia cepacia complex in cystic fibrosis: critical gaps in diagnosis and therapy. Ann Med. 2024; 56(1): 2307503. DOI: https://doi.org/10.1080/07853890.2024.2307503
Tang KW, Millar BC, Moore JE. Antimicrobial resistance (AMR). Br J Biomed Sci. 2023; 80: 11387. DOI: https://doi.org/10.3389/bjbs.2023.11387
Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Wayne (PA): CLSI; 2010.
Batool A, Yaqoob A, Anwar Z, Joshi LT, Batool R, Lone D, et al. Outbreak investigation of NDM-producing Burkholderia cepacia causing neonatal sepsis in Pakistan. Future Microbiol. 2023; 18: 1159–69. DOI: https://doi.org/10.2217/fmb-2023-0063
Irfan R, Amer A, Mirza IA, Hussain W, Sarwar M, Akhtar M, et al. Burkholderia cepacia: an emerging superbug in intensive care unit settings of tertiary care hospitals in Pakistan. Pak Armed Forces Med J. 2022; 72(5): 1826–30.
DOI: https://doi.org/10.51253/pafmj.v72i5.7635
Tasleem S, Ansari MS, Dhillo AK, Ishaque S. Outbreak of Burkholderia cepaciae bacteremia in neonatal units of a public sector hospital in Karachi, Pakistan. Pak J Med Health Sci. 2023; 17(06): 466–8. DOI: http://dx.doi.org/10.53350/pjmhs2023176466
Saeed M, Rasheed F, Rasool MH, Hayat S, Khurshid M. Carbapenem-resistant Burkholderia cepacia complex isolates carrying blaNDM-1 and blaNDM-5 in ventilator-associated pneumonia patients and contaminated ventilator tubing. Transbound Emerg Dis. 2024; 2024(1) :3352135. DOI: https://doi.org/10.1155/2024/3352135
Popescu CR, et al. Neonatal sepsis in low-income countries: epidemiology, diagnosis and prevention. Expert Rev Anti Infect Ther. 2020; 18(5): 443–52. DOI: https://doi.org/10.1080/14787210.2020.1732818
Özdemir YE, Kaplan-Yapar B, Borcak D, Canbolat-Ünlü E, Bayramlar OF, Çizmeci Z, et al. Antimicrobial susceptibility profiles and key determinants for mortality in Burkholderia cepacia complex infections. Infect Dis Clin Microbiol. 2023; 5(3): 239-50. DOI: https://doi.org/10.36519/idcm.2023.259
Siddiqui T, Sahu C, Patel SS, Ghoshal U. Clinical and microbiological profile of patients with bloodstream infections caused by Burkholderia cepacia complex. J Lab Physicians. 2022; 14(03): 312–6. DOI: https://doi.org/10.1055/s-0042-1742634
Bharara T, et al. Investigation of Burkholderia cepacia complex bacteremia outbreak in a neonatal intensive care unit: a case series. J Med Case Rep. 2020; 14 (1): 76. DOI: https://doi.org/10.1186/s13256-020-02415-8
Okomo U, Senghore M, Darboe S, Bojang E, Zaman SMA, Hossain MJ, et al. Investigation of sequential outbreaks of Burkholderia cepacia and multidrug-resistant extended-spectrum β-lactamase-producing Klebsiella species in a West African tertiary hospital neonatal unit: A retrospective genomic analysis. Lancet Microbe. 2020; 1(3): e119–29. DOI: https://doi.org/10.1016/s2666-5247(20)30061-6
Häfliger E, Atkinson A, Marschall J. Systematic review of healthcare-associated Burkholderia cepacia complex outbreaks: presentation, causes and outbreak control. Infect Prev Pract. 2020; 2(3): 100082. DOI: https://doi.org/10.1016/j.infpip.2020.100082
Branstetter JW, Yarbrough A, Poole C. Management of cepacia syndrome with a combination of intravenous and inhaled antimicrobials in a non-cystic fibrosis pediatric patient. J Pediatr Pharmacol Ther. 2020; 25(8): 730–4. DOI: https://doi.org/10.5863/1551-6776-25.8.730
Dagenais RV, Quon BS, Franciosi AN. Nebulized levofloxacin for chronic Burkholderia cenocepacia pulmonary infection in cystic fibrosis: A case report. Respir Med Case Rep. 2022; 40: 101772. DOI: https://doi.org/10.1016/j.rmcr.2022.101772
Suzuki Y, Lee T, Togawa R, Sato R, Yamada R, Tomita H, et al. Efficacy of combination antibiotic therapy including inhaled tobramycin on Burkholderia cepacia pneumonia in a non-cystic fibrosis patient. IDCases. 2024; 38: e02081.
DOI: https://doi.org/10.1016/j.idcr.2024.e02081
Moore JE, McCaughan J, Rendall JC, Millar BC. Case report: the conundrum of what to pick? Antibiotic susceptibility variability in Burkholderia cenocepacia in cystic fibrosis: implications for antibiotic susceptibility testing and treatment. Br J Biomed Sci. 2024; 81: 12749. DOI: https://doi.org/10.3389/bjbs.2024.12749
Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Wayne (PA): CLSI; 2025.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Professor Seema Irfan, Fizza Farooqui, Kiran Iqbal, Professor Afia Zafar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
